Vesalius Biocapital Partners
Vesalius Biocapital III is a later-stage European life sciences venture capital fund based in Strassen, Luxembourg, with €120 million in assets under management. Launched in April 2017 and closed in May 2019, the fund focuses on investing in innovative companies in drug development, medical devices and diagnostics, and eHealth/mHealth. It aims to address unmet medical needs and supports companies with strong intellectual property. Managed by Vesalius Biocapital Partners, the fund targets investments in 10 to 15 companies, typically deploying between $1 million and $10 million per investment.
Investing activity
Vesalius Biocapital Partners is listed on AI Lounge as a venture capital investor based in Los Angeles, California, United States. The deals desk records Series A and later AI rounds and seeds over $10M, so smaller checks may not show here yet.
Deals
Frequently asked questions about Vesalius Biocapital Partners
Where is Vesalius Biocapital Partners based?
Vesalius Biocapital Partners is based in Los Angeles, California, United States.
How can founders reach Vesalius Biocapital Partners?
Founders on AI Lounge can see Vesalius Biocapital Partners's contact details in AI Investor Contacts (paid plans), check for a warm introduction through members who worked with the firm under Warm Paths, and add Vesalius Biocapital Partners to their Investor Pipeline to track the conversation.